Melanotan II Evidence Guide
Evidence for Melanotan II is too preliminary to support a research protocol with confidence, and its safety profile is a genuine concern - not approved by any regulatory agency, associated with spontaneous erections, blood pressure changes, nausea, and multiple case reports of melanoma in pre-existing nevi. Of the Sexual Health compounds, PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire and has a far superior safety and evidence profile.
Our Take
Evidence for Melanotan II is too preliminary to support a research protocol with confidence, and its safety profile is a genuine concern - not approved by any regulatory agency, associated with spontaneous erections, blood pressure changes, nausea, and multiple case reports of melanoma in pre-existing nevi. Of the Sexual Health compounds, PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire and has a far superior safety and evidence profile.
- Evidence context
- No validated therapeutic application - melanocortin receptor pharmacology research (with caution)
- Evidence grade
- Level C
- Confidence
- Low
- Reference context
- Reported research reference: No safe established human protocol - regulatory agencies have not approved this compound
Benefits and Evidence
- Skin Pigmentation: Level C, includes human evidence - Clinical trials demonstrated significant skin darkening with subcutaneous MT-II administration. Pigmentation occurs without UV exposure, though UV co-exposure enhances results.
- Erectile Function: Level C, includes human evidence - Wessells et al. (2000, Int J Impot Res) reported that SC melanotan II (0.025 mg/kg) induced erections in 12/19 men within 1-5 h, with 8/10 erectile dysfunction patients showing improved rigidity; Dorr et al. (1996, Life Sci) first documented spontaneous erections in Phase I melanoma-tanning trials, leading to bremelanotide (PT-141) development.
- Nausea & Side Effects: Level C, includes human evidence - Facial flushing, nausea, and fatigue are commonly reported. Mole darkening and potential for melanoma concern have been raised in case reports.
Side Effects and Warnings
- Nausea and facial flushing
- Darkening of existing moles and nevi
- Fatigue and drowsiness
- Spontaneous erections
- Elevated blood pressure
- Injection site reactions
- Not approved by any regulatory agency for human use
- Potential risk of melanoma promotion due to melanocyte stimulation - patients with family history should avoid
Research Dosage References
- <strong>Subcutaneous injection</strong> - 0.25-1.0 mg - Daily during loading, then weekly maintenance - Not approved for human use. Doses referenced from clinical research only. Loading phase typically 0.5 mg/day for 5-7 days.
- <strong>Nasal spray</strong> - 0.5-1.0 mg - As studied in research settings - Lower bioavailability than injection. Nasal formulations have been studied but not approved.
Mechanism of Action
Melanotan II acts as a non-selective agonist of melanocortin receptors (MC1R-MC5R): 1. MC1R activation: Stimulates melanogenesis in melanocytes, increasing eumelanin production and skin pigmentation without UV exposure. 2. MC3R/MC4R activation: Produces effects on sexual function through central nervous system pathways, increasing libido and facilitating erections. 3. MC4R-mediated appetite suppression: Reduces food intake through hypothalamic melanocortin signaling. 4. Cardiovascular effects: MC receptor activation can cause transient increases in blood pressure and heart rate.
Legal Status
Not FDA-approved. Classified as an unscheduled research peptide in the United States. Banned for sale as a consumer product in many countries including Australia and the UK. Prohibited by WADA in competitive sports.
Primary Sources
- Subcutaneous administration of melanotan II to human volunteers: a phase I study. Journal of Clinical Pharmacology, 1996.
- Melanotan II: an investigation of usage, effects, and safety. Drug Testing and Analysis, 2012.
- Melanocortin receptor agonists and antagonists in the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 2003.
Quick Answers
Where is the strongest evidence for Melanotan II?
Evidence for Melanotan II is too preliminary to support a research protocol with confidence, and its safety profile is a genuine concern - not approved by any regulatory agency, associated with spontaneous erections, blood pressure changes, nausea, and multiple case reports of melanoma in pre-existing nevi. Of the Sexual Health compounds, PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire and has a far superior safety and evidence profile. Evidence context: No validated therapeutic application - melanocortin receptor pharmacology research (with caution).
What are the main side effects of Melanotan II?
Melanotan II side effects and warning signals include Nausea and facial flushing, Darkening of existing moles and nevi, Fatigue and drowsiness, Spontaneous erections, and Elevated blood pressure.
What evidence level is Melanotan II?
Melanotan II is rated Level C; the listed research status is Preclinical.